Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TBPH message board posts where the ticker symbol TBPH has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TBPH SEC Filings

Filings Format Description Filing Date File/Film Number
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001047469-18-001961 (34 Act)  Size: 1 MB
2018-03-21 001-36033
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001104659-18-015270 (33 Act)  Size: 149 KB
2018-03-06 333-223470
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001047469-18-001160 (34 Act)  Size: 10 MB
2018-02-28 001-36033
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-012808 (34 Act)  Size: 1 MB
2018-02-27 001-36033
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002615 Size: 4 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002614 Size: 4 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002613 Size: 4 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002612 Size: 4 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002611 Size: 4 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-002610 Size: 4 KB
More TBPH SEC Filings

Related news from
Wed, 21 Mar 2018
12:30:00 +0000
Theravance Biopharma to Present at the 17th Annual Needham Healthcare Conference
DUBLIN, March 21, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that members of management will present a corporate overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 9:00 a.m. ET.  The conference will be held from March 27 - 28 at the Westin Grand Central Hotel in New York. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
Thu, 15 Mar 2018
14:30:47 +0000
Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis but 1% higher on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Cubicin generated revenues of $40 million and $52 million, respectively, compared with $82 million and $36 million in 4Q16, which reflected a ~51% decline and 43% rise, respectively, YoY. In fiscal 2017, Cubicin reported revenues of $382 million, compared with $1.1 billion in 2016.
Tue, 06 Mar 2018
13:03:23 +0000
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH
Wed, 28 Feb 2018
20:44:14 +0000
Edited Transcript of TBPH earnings conference call or presentation 27-Feb-18 10:00pm GMT
Q4 2017 Theravance Biopharma Inc Earnings Call
Wed, 28 Feb 2018
14:20:02 +0000
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
Wed, 28 Feb 2018
10:04:27 +0000
Theravance Bio reports 4Q loss
The George Town, Cayman Islands-based company said it had a loss of $1.64 per share. The biopharmaceutical company posted revenue of $4.5 million in the period. For the year, the company reported that ...
Tue, 27 Feb 2018
21:05:00 +0000
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Multiple Programs Poised to Advance in 2018 DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported ...
Tue, 27 Feb 2018
18:30:00 +0000
Theravance Biopharma Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Theravance Biopharma Inc NASDAQ: TBPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 5:00 PM Eastern ...
Tue, 27 Feb 2018
16:41:05 +0000
Theravance Biopharma Q4 Earnings Outlook
Don't be caught off-guard: Theravance Biopharma (NASDAQ: TBPH ) releases its next round of earnings Tuesday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...
Wed, 21 Feb 2018
13:03:00 +0000
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Johnson & Johnson has had huge success with small deals in the past. Here's a look at the latest bet.
Tue, 20 Feb 2018
13:30:00 +0000
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2017 after market close on Tuesday, February 27, 2018. An accompanying conference call will be held at 5:00 pm ET on February 27, 2018.  To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 3999284. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through March 29, 2018.
Thu, 15 Feb 2018
13:30:00 +0000
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
DUBLIN, Feb. 15, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the submission of the landmark IMPACT study data to the European Medicines Agency (EMA) as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler.
Fri, 09 Feb 2018
12:10:00 +0000
Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473
Stock Monitor: Enanta Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / has just released a free research report on Theravance Biopharma, Inc. (NASDAQ: TBPH ...
Thu, 08 Feb 2018
16:26:04 +0000
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Wed, 07 Feb 2018
16:10:21 +0000
Why Theravance Biopharma Shares Are Soaring
Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech.
Wed, 07 Feb 2018
12:30:00 +0000
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases
DUBLIN, Feb. 7, 2018 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today announced that it has entered into a global co-development and commercialization agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for TD-1473 and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. Under the terms of the agreement, Theravance Biopharma will receive an upfront payment of $100 million and will be eligible to receive up to an additional $900 million in potential payments, if Janssen elects to remain in the collaboration following the completion of certain Phase 2 activities, as described below.
Tue, 30 Jan 2018
16:14:04 +0000
Theravance's NDA for COPD Candidate Gets FDA Acceptance
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.
Tue, 30 Jan 2018
13:57:04 +0000
Biotech Movers: Aradigm Corporation, Theravance Biopharma, Inc. and Mylan NV
Aradigm Corporation (NASDAQ:ARDM), Theravance Biopharma, Inc. (NASDAQ:TBPH) and Mylan NV (NASDAQ:MYL) are all hitting headlines with each putting out an update relating to one of their respective development programs. Here’s a look at the news and what it means for all three companies. Aradigm This one is rooted in the release of a regulatory update […] The post Biotech Movers: Aradigm Corporation, Theravance Biopharma, Inc. and Mylan NV appeared first on Market Exclusive.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "No friend, no book, no broker, no advisor, no expert has ever provided a tenth what I am able to find here. The best money I have EVER spent, is for membership." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards